GRDX logo

GRIDAI TECHNOLOGIES CORP

GRDXNASDAQ
🏆 #4962 by market capEarnings Nov 16US Equity
$3.19▼ $0.27 (−8.33%)
After hours · at close
🔔
Track GRDX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 8.3%
7d▼ 16.9%
14d▲ 8.5%
30d▼ 21.2%
ytd▼ 29.0%
1y▼ 35.3%
🏦Market Cap
$11M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
-1532.5%
Thin
💵FCF Margin
-5064.9%
Thin
⚖️P/S Ratio
71.9x
Expensive
Otter Score
72
Fair

Trading Snapshot

Day Range
$3.15 – $3.22
52-Week Range
$1.87 – $6.93
Volume
$2.12B
Avg Volume
$1.76B
Shares Outstanding
3.4M
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$36,251
Last Q Revenue
$85,876
P/E Ratio
-0.8
P/S Ratio
71.9x
EPS (TTM)
$-3.19
Dividend Yield
0.00%
Dilution (1yr)
−11.1%

Why Investors Own GRDX

  • ✓High-growth profile — revenue up +37.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 28% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GRDX logo

GRIDAI TECHNOLOGIES CORP

GRDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$36K▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$7M▼ −54.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▼ −38.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.2M▼ −11.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$1M▼ −$1M YoY
StockOtter · stockotter.space

About GRIDAI TECHNOLOGIES CORP

GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$4.19
▲ +31.5% Upside
High Target$4.54
Low Target$3.25
Based on 32 analysts

Latest News & Updates

🚀
CNBC·2h ago

GRIDAI TECHNOLOGIES CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift GRDX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

GRIDAI TECHNOLOGIES CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.